## Andrea Fagiolini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/395838/publications.pdf

Version: 2024-02-01

252 papers 10,749 citations

52 h-index 92 g-index

282 all docs 282 docs citations

times ranked

282

9355 citing authors

#	Article	IF	CITATIONS
1	Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. JAMA Psychiatry, 2019, 76, 893.	11.0	472
2	Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disorders, 2005, 7, 424-430.	1.9	396
3	Obesity as a Correlate of Outcome in Patients With Bipolar I Disorder. American Journal of Psychiatry, 2003, 160, 112-117.	7.2	368
4	The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry, 2014, 13, 275-287.	10.4	346
5	Medication Effects in Neuroimaging Studies of Bipolar Disorder. American Journal of Psychiatry, 2008, 165, 313-320.	7.2	312
6	Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disorders, 2009, 11, 657-662.	1.9	220
7	The bipolar spectrum: a clinical reality in search of diagnostic criteria and an assessment methodology. Journal of Affective Disorders, 1999, 54, 319-328.	4.1	210
8	Assessment and management of agitation in psychiatry: Expert consensus. World Journal of Biological Psychiatry, 2016, 17, 86-128.	2.6	204
9	Anxiety as a Correlate of Response to the Acute Treatment of Bipolar I Disorder. American Journal of Psychiatry, 2000, 157, 956-962.	7.2	201
10	The Mood Spectrum in Unipolar and Bipolar Disorder: Arguments for a Unitary Approach. American Journal of Psychiatry, 2004, 161, 1264-1269.	7.2	200
11	Using Computerized Adaptive Testing to Reduce the Burden of Mental Health Assessment. Psychiatric Services, 2008, 59, 361-368.	2.0	200
12	Functional impairment in the remission phase of bipolar disorder. Bipolar Disorders, 2005, 7, 281-285.	1.9	174
13	Prevalence of Obesity and Weight Change During Treatment in Patients With Bipolar I Disorder. Journal of Clinical Psychiatry, 2002, 63, 528-533.	2.2	172
14	Rediscovering Trazodone for the Treatment of Major Depressive Disorder. CNS Drugs, 2012, 26, 1033-1049.	5.9	170
15	The Effects of Undertreated Chronic Medical Illnesses in Patients With Severe Mental Disorders. Journal of Clinical Psychiatry, 2009, 70, 22-29.	2.2	165
16	Clinical Significance of Lifetime Panic Spectrum Symptoms in the Treatment of Patients With Bipolar I Disorder. Archives of General Psychiatry, 2002, 59, 905.	12.3	164
17	The Role of Interpersonal and Social Rhythm Therapy in Improving Occupational Functioning in Patients With Bipolar I Disorder. American Journal of Psychiatry, 2008, 165, 1559-1565.	7.2	146
18	Schizoaffective disorder: diagnostic issues and future recommendations. Bipolar Disorders, 2008, 10, 215-230.	1.9	142

#	Article	IF	CITATIONS
19	Prevalence, chronicity, burden and borders of bipolar disorder. Journal of Affective Disorders, 2013, 148, 161-169.	4.1	141
20	Measuring Mood Spectrum: Comparison of interview (SCI-MOODS) and self-report (MOODS-SR) instruments. Comprehensive Psychiatry, 2002, 43, 69-73.	3.1	134
21	Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia. Bipolar Disorders, 2009, 11, 701-710.	1.9	133
22	Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy. Psychological Medicine, 2011, 41, 151-162.	4.5	123
23	Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2â€∫years. Bipolar Disorders, 2006, 8, 566-575.	1.9	118
24	Bipolar Disorder and the Metabolic Syndrome. CNS Drugs, 2008, 22, 655-669.	5.9	115
25	Influence of Panic-Agoraphobic Spectrum Symptoms on Treatment Response in Patients With Recurrent Major Depression. American Journal of Psychiatry, 2000, 157, 1101-1107.	7.2	113
26	Is treatment-resistant depression a unique subtype of depression?. Biological Psychiatry, 2003, 53, 640-648.	1.3	111
27	Association between stressful life events and autoimmune diseases: A systematic review and meta-analysis of retrospective case–control studies. Autoimmunity Reviews, 2016, 15, 325-334.	5.8	97
28	The interplay among psychopathology, personal resources, contextâ€related factors and realâ€life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and nonâ€recovered patients. World Psychiatry, 2020, 19, 81-91.	10.4	96
29	Suicide Attempts in Patients With Bipolar I Disorder During Acute and Maintenance Phases of Intensive Treatment With Pharmacotherapy and Adjunctive Psychotherapy. American Journal of Psychiatry, 2002, 159, 1160-1164.	7.2	93
30	Are adults with bipolar disorder active? Objectively measured physical activity and sedentary behavior using accelerometry. Journal of Affective Disorders, 2014, 152-154, 498-504.	4.1	93
31	Inflammation, Serotonin and Major Depression. Current Drug Targets, 2013, 14, 571-577.	2.1	93
32	A multidimensional spectrum approach to post-traumatic stress disorder: comparison between the Structured Clinical Interview for Trauma and Loss Spectrum (SCI-TALS) and the Self-Report instrument (TALS-SR). Comprehensive Psychiatry, 2009, 50, 485-490.	3.1	91
33	Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. JAMA Psychiatry, 2021, 78, 550.	11.0	89
34	Suicide Attempts and Ideation in Patients With Bipolar I Disorder. Journal of Clinical Psychiatry, 2004, 65, 509-514.	2.2	85
35	COVID-19 Diary From a Psychiatry Department in Italy. Journal of Clinical Psychiatry, 2020, 81, .	2.2	81
36	Adult separation anxiety: psychometric properties of a new structured clinical interview. Journal of Psychiatric Research, 2002, 36, 77-86.	3.1	78

#	Article	lF	CITATIONS
37	Medical Burden in Late-Life Bipolar and Major Depressive Disorders. American Journal of Geriatric Psychiatry, 2008, 16, 194-200.	1.2	78
38	Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. Journal of Psychiatric Research, 2008, 42, 956-961.	3.1	76
39	Obesity in Patients With Bipolar Disorder. Journal of Clinical Psychiatry, 2006, 67, 904-915.	2.2	76
40	Validity and reliability of a new instrument for assessing mood symptomatology: the Structured Clinical Interview for Mood Spectrum (SCI-MOODS). International Journal of Methods in Psychiatric Research, 1999, 8, 71-82.	2.1	75
41	Lithium and suicide prevention in mood disorders and in the general population: A systematic review. Neuroscience and Biobehavioral Reviews, 2020, 116, 142-153.	6.1	68
42	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry, 2022, 27, 1286-1299.	7.9	68
43	Call to action regarding the vascularâ€bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders. Bipolar Disorders, 2020, 22, 440-460.	1.9	66
44	Prevalence and Clinical Correlates of Medical Comorbidities in Patients With Bipolar I Disorder. Journal of Clinical Psychiatry, 2006, 67, 783-788.	2.2	64
45	Off-label uses of trazodone: a review. Expert Opinion on Pharmacotherapy, 2012, 13, 1707-1717.	1.8	63
46	Adult obsessive–compulsive disorder and quality of life outcomes: A systematic review and meta-analysis. Asian Journal of Psychiatry, 2016, 22, 41-52.	2.0	62
47	Prevalence and correlates of eating disorder co-morbidity in patients with bipolar disorder. Psychiatry Research, 2008, 161, 51-58.	3.3	61
48	Effect of Age, Weight, and CYP2C19 Genotype on Escitalopram Exposure. Journal of Clinical Pharmacology, 2010, 50, 62-72.	2.0	60
49	Correlates of autistic traits among patients with borderline personality disorder. Comprehensive Psychiatry, 2018, 83, 7-11.	3.1	60
50	Conceptual underpinnings and empirical support for the mood spectrum. Psychiatric Clinics of North America, 2002, 25, 699-712.	1.3	59
51	Personality pathology and outcome in recurrently depressed women over 2 years of maintenance interpersonal psychotherapy. Psychological Medicine, 2004, 34, 659-669.	4.5	56
52	A Psychoeducational Program for Weight Loss in Patients who have Experienced Weight Gain during Antipsychotic Treatment with Olanzapine. Pharmacopsychiatry, 2008, 41, 17-23.	3.3	54
53	The Use of Antidepressants in Bipolar Disorder. Journal of Clinical Psychiatry, 2008, 69, 1307-1318.	2.2	54
54	Disorganization and real-world functioning in schizophrenia: Results from the multicenter study of the Italian Network for Research on Psychoses. Schizophrenia Research, 2018, 201, 105-112.	2.0	52

#	Article	IF	CITATIONS
55	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. BMC Medicine, 2020, 18, 215.	5.5	52
56	Chronotype and Body Composition in Bipolar Disorder. Chronobiology International, 2009, 26, 780-788.	2.0	51
57	Phenomenology of manic episodes according to the presence or absence of depressive features as defined in DSM-5: Results from the IMPACT self-reported online survey. Journal of Affective Disorders, 2014, 156, 206-213.	4.1	51
58	Quality of life, anxiety and depression in Sarcoidosis. General Hospital Psychiatry, 2008, 30, 441-445.	2.4	50
59	Lithium in late-life mania: a systematic review. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 755-766.	2.2	50
60	The structure of lifetime manic–hypomanic spectrum. Journal of Affective Disorders, 2009, 112, 59-70.	4.1	49
61	Diagnosis, Epidemiology and Management of Mixed States in Bipolar Disorder. CNS Drugs, 2015, 29, 725-740.	5.9	48
62	Impact of concurrent naturalistic pharmacotherapy on psychotherapy of complicated grief. Psychiatry Research, 2008, 159, 31-36.	3.3	47
63	The factor structure of lifetime depressive spectrum in patients with unipolar depression. Journal of Affective Disorders, 2009, 115, 87-99.	4.1	46
64	Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment. Journal of Affective Disorders, 2021, 283, 472-479.	4.1	46
65	Relationship between sunlight and the age of onset of bipolar disorder: An international multisite study. Journal of Affective Disorders, 2014, 167, 104-111.	4.1	43
66	Off-Label Trazodone Prescription: Evidence, Benefits and Risks. Current Pharmaceutical Design, 2015, 21, 3343-3351.	1.9	43
67	Mental health, pain symptoms and systemic comorbidities in women with endometriosis: a cross-sectional study. Journal of Psychosomatic Obstetrics and Gynaecology, 2018, 39, 315-320.	2.1	42
68	Cardiovascular Disease and Bipolar Disorder. Journal of Clinical Psychiatry, 2012, 73, 1563-1565.	2.2	42
69	Hypothyroidism in patients with Bipolar I Disorder treated primarily with lithium. Epidemiologia E Psichiatria Sociale, 2006, 15, 123-127.	0.9	41
70	The Role of Psychomotor Activation in Discriminating Unipolar From Bipolar Disorders. Journal of Clinical Psychiatry, 2012, 73, 22-28.	2.2	41
71	Shared and divergent neurocognitive impairments in adult patients with schizophrenia and bipolar disorder: Whither the evidence?. Neuroscience and Biobehavioral Reviews, 2016, 61, 66-89.	6.1	40
72	The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar Disorders, 2020, 22, 831-840.	1.9	40

#	Article	IF	Citations
73	Serotonin gene polymorphisms and bipolar I disorder: Focus on the serotonin transporter. Annals of Medicine, 2005, 37, 590-602.	3.8	39
74	Impact of sunlight on the age of onset of bipolar disorder. Bipolar Disorders, 2012, 14, 654-663.	1.9	39
75	Influence of light exposure during early life on the age of onset of bipolar disorder. Journal of Psychiatric Research, 2015, 64, 1-8.	3.1	39
76	Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. World Journal of Biological Psychiatry, 2021, 22, 1-15.	2.6	38
77	Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial. Depression and Anxiety, 2011, 28, 303-309.	4.1	37
78	Internet use by patients with bipolar disorder: Results from an international multisite survey. Psychiatry Research, 2016, 242, 388-394.	3.3	36
79	Metabolic Syndrome in Patients With Bipolar Disorder. Journal of Clinical Psychiatry, 2008, 69, 678-679.	2.2	36
80	Does psychomotor retardation define a clinically relevant phenotype of unipolar depression?. Journal of Affective Disorders, 2011, 129, 296-300.	4.1	35
81	Online information seeking by patients with bipolar disorder: results from an international multisite survey. International Journal of Bipolar Disorders, 2016, 4, 17.	2.2	35
82	Quality of life in children and adolescents with obsessive& ndash; compulsive disorder: a systematic review and meta-analysis. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 597-608.	2.2	35
83	Persistent Posttraumatic Stress Disorder Following September 11 in Patients With Bipolar Disorder. Journal of Clinical Psychiatry, 2006, 67, 394-399.	2.2	35
84	Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice. Journal of Affective Disorders, 2018, 228, 229-237.	4.1	34
85	<p>Rumination, posttraumatic stress disorder, and mood symptoms in borderline personality disorder</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1231-1238.	2.2	34
86	The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 285-294.	3.2	33
87	The Microbiome: A New Target for Research and Treatment of Schizophrenia and its Resistant Presentations? A Systematic Literature Search and Review. Frontiers in Pharmacology, 2018, 9, 1040.	3.5	33
88	Prevalence and Correlates of Vitamin D Deficiency in a Sample of 290 Inpatients With Mental Illness. Frontiers in Psychiatry, 2019, 10, 167.	2.6	33
89	Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies. Psychiatry Research, 2017, 247, 257-264.	3.3	32
90	Enhancing outcomes in patients with bipolar disorder: results from the Bipolar Disorder Center for Pennsylvanians Study. Bipolar Disorders, 2009, 11, 382-390.	1.9	30

#	Article	IF	Citations
91	Catatonia and Neuroleptic Malignant Syndrome. Journal of Nervous and Mental Disease, 2013, 201, 36-42.	1.0	30
92	Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel. Annals of General Psychiatry, 2020, 19, 55.	2.7	30
93	Gender Differences in Bipolar Disorder Type 1. Journal of Nervous and Mental Disease, 2007, 195, 93-96.	1.0	29
94	Investigating the Relationship between Autistic Traits, Ruminative Thinking, and Suicidality in a Clinical Sample of Subjects with Bipolar Disorder and Borderline Personality Disorder. Brain Sciences, 2021, 11, 621.	2.3	29
95	A Prospective Observational Study of Obesity, Body Composition, and Insulin Resistance in 18 Women With Bipolar Disorder and 17 Matched Control Subjects. Journal of Clinical Psychiatry, 2008, 69, 1892-1900.	2.2	29
96	A Pilot Study of Standardized Treatment in Geriatric Bipolar Disorder. American Journal of Geriatric Psychiatry, 2005, 13, 319-323.	1.2	28
97	Eating disorders and illness burden in patients with bipolar spectrum disorders. Comprehensive Psychiatry, 2007, 48, 516-521.	3.1	28
98	Eating disorders and autism spectrum: links and risks. CNS Spectrums, 2022, 27, 272-280.	1.2	28
99	A Pilot Study of Standardized Treatment in Geriatric Bipolar Disorder. American Journal of Geriatric Psychiatry, 2005, 13, 319-323.	1.2	28
100	The Importance of Routine for Preventing Recurrence in Bipolar Disorder. American Journal of Psychiatry, 2006, 163, 981-985.	7.2	27
101	Weight gain and metabolic issues of medicines used for bipolar disorder. Current Psychiatry Reports, 2007, 9, 521-528.	4.5	27
102	Incidence and predictors of relapse during continuation treatment of major depression with SSRI, interpersonal psychotherapy, or their combination. Depression and Anxiety, 2011, 28, 955-962.	4.1	27
103	Rethinking the role of long-acting atypical antipsychotics in the community setting. International Clinical Psychopharmacology, 2012, 27, 1.	1.7	27
104	Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin. Journal of Psychiatric Research, 2021, 133, 82-92.	3.1	27
105	Self-reported cognitive problems predict employment trajectory in patients with bipolar I disorder. Journal of Affective Disorders, 2010, 124, 324-328.	4.1	26
106	A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. International Clinical Psychopharmacology, 2020, 35, 137-146.	1.7	26
107	Association between solar insolation and a history of suicide attempts in bipolar I disorder. Journal of Psychiatric Research, 2019, 113, 1-9.	3.1	25
108	S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review. Annals of General Psychiatry, 2020, 19, 50.	2.7	25

#	Article	IF	CITATIONS
109	DSM-5 and ICD-11 criteria for bipolar disorder: Implications for the prevalence of bipolar disorder and validity of the diagnosis $\hat{a} \in A$ narrative review from the ECNP bipolar disorders network. European Neuropsychopharmacology, 2021, 47, 54-61.	0.7	25
110	Treatmentâ€emergent mania/hypomania in unipolar patients. Bipolar Disorders, 2008, 10, 726-732.	1.9	24
111	Addressing the challenges of a cross-national investigation: lessons from the Pittsburgh-Pisa study of treatment-relevant phenotypes of unipolar depression. Clinical Trials, 2008, 5, 253-261.	1.6	24
112	Glutamate system as target for development of novel antidepressants. CNS Spectrums, 2013, 18, 188-198.	1.2	24
113	Psychological and Brain Connectivity Changes Following Trauma-Focused CBT and EMDR Treatment in Single-Episode PTSD Patients. Frontiers in Psychology, 2019, 10, 129.	2.1	24
114	Mood and anxiety spectrum as a means to identify clinically relevant subtypes of bipolar I disorder. Bipolar Disorders, 2007, 9, 462-467.	1.9	23
115	Which factors delay treatment in bipolar disorder? A nationwide study focussed on duration of untreated illness. Microbial Biotechnology, 2021, 15, 1136-1145.	1.7	23
116	Tolerability of Combined Treatment With Lithium and Paroxetine in Patients With Bipolar Disorder and Depression. Journal of Clinical Psychopharmacology, 2001, 21, 474-478.	1.4	22
117	The panic-agoraphobic spectrum: development, description, and clinical significance. Psychiatric Clinics of North America, 2002, 25, 739-756.	1.3	22
118	Newer antipsychotics and the rabbit syndrome. Clinical Practice and Epidemiology in Mental Health, 2007, 3, 6.	1.2	22
119	Aripiprazole in the Treatment??of Schizophrenia. Clinical Drug Investigation, 2007, 27, 1-13.	2.2	22
120	Effects of an Educational Intervention on Weight Gain in Patients Treated With Antipsychotics. Journal of Clinical Psychopharmacology, 2006, 26, 462-466.	1.4	21
121	Sexual Disorders in Subjects Treated for Mood and Anxiety Diseases. Journal of Clinical Psychopharmacology, 2007, 27, 310-312.	1.4	21
122	Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532094270.	2.7	21
123	Is Lifetime Separation Anxiety a Manifestation of Panic Spectrum?. CNS Spectrums, 1998, 3, 63-72.	1.2	20
124	Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice. Expert Opinion on Pharmacotherapy, 2019, 20, 679-690.	1.8	20
125	Morphovolumetric changes after EMDR treatment in drug-na $\tilde{A}$ ve PTSD patients. Rivista Di Psichiatria, 2017, 52, 24-31.	0.6	20
126	Aripiprazole Augmentation in Clozapine-Associated Obsessive-Compulsive Symptoms. Journal of Clinical Psychopharmacology, 2011, 31, 375-376.	1.4	19

#	Article	IF	Citations
127	Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists. Expert Opinion on Pharmacotherapy, 2015, 16, 727-737.	1.8	19
128	Psychotic versus non-psychotic bipolar disorder: Socio-demographic and clinical profiles in an Italian nationwide study. Australian and New Zealand Journal of Psychiatry, 2019, 53, 772-781.	2.3	19
129	Photosensitivity in panic disorder. Depression and Anxiety, 2009, 26, E34-E36.	4.1	18
130	Psychoeducational intervention focused on healthy living improves psychopathological severity and lifestyle quality in psychiatric patients: preliminary findings from a controlled study. Journal of Mental Health, 2017, 26, 271-275.	1.9	18
131	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1173-1182.	2.3	18
132	Drug safety evaluation of aripiprazole in bipolar disorder. Expert Opinion on Drug Safety, 2019, 18, 455-463.	2.4	18
133	Celiac and non-celiac gluten sensitivity: a review on the association with schizophrenia and mood disorders. Autoimmunity Highlights, 2014, 5, 55-61.	3.9	17
134	Personalized and precision medicine as informants for treatment management of bipolar disorder. International Clinical Psychopharmacology, 2019, 34, 189-205.	1.7	17
135	Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action. European Neuropsychopharmacology, 2020, 36, 121-136.	0.7	17
136	Interpersonal psychotherapy for depression with panic spectrum symptoms: a pilot study. Depression and Anxiety, 2005, 21, 140-142.	4.1	16
137	Pharmacotherapy of Binge-Eating Disorder. Journal of Addiction Medicine, 2015, 9, 1-19.	2.6	16
138	The impact of affective temperaments on clinical and functional outcome of Bipolar I patients that initiated or changed pharmacological treatment for mania. Psychiatry Research, 2018, 261, 473-480.	3.3	16
139	Using sertraline in postpartum and breastfeeding: balancing risks and benefits. Expert Opinion on Drug Safety, 2018, 17, 719-725.	2.4	16
140	Clinical indicators for the use of antidepressants in the treatment of bipolar I depression. Bipolar Disorders, 2002, 4, 277-282.	1.9	15
141	Practical guidance for prescribing with aripiprazole in bipolar disorder. Current Medical Research and Opinion, 2008, 24, 2691-2702.	1.9	15
142	Strategies for successful clinical management of schizophrenia with ziprasidone. Expert Opinion on Pharmacotherapy, 2010, 11, 2199-2220.	1.8	15
143	Patterns of Antidepressant Use in Italy: Therapy Duration, Adherence and Switching. Clinical Drug Investigation, 2015, 35, 735-742.	2.2	15
144	Socio-demographic and clinical characterization of patients with Bipolar Disorder I vs II: a Nationwide Italian Study. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 169-177.	3.2	15

#	Article	IF	CITATIONS
145	Gender-related differences in patients with bipolar disorder: a nationwide study. CNS Spectrums, 2019, 24, 589-596.	1.2	15
146	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. European Psychiatry, 2021, 64, e7.	0.2	15
147	Validation of the Italian version of the Functioning Assessment Short Test (FAST) for bipolar disorder. Epidemiology and Psychiatric Sciences, 2013, 22, 187-194.	3.9	14
148	Telepsychiatry: new perspectives and open issues. CNS Spectrums, 2014, 19, 479-481.	1.2	14
149	Understanding the emotions of patients with inadequate response to antidepressant treatments: results of an international online survey in patients with major depressive disorder. BMC Psychiatry, 2018, 18, 33.	2.6	14
150	Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting. Journal of Affective Disorders, 2021, 294, 924-931.	4.1	14
151	Subcutaneous Apomorphine for Neuroleptic Malignant Syndrome. American Journal of Psychiatry, 2006, 163, 1450-1451.	7.2	13
152	The Effect of Reporting Methods for Dosing Times on the Estimation of Pharmacokinetic Parameters of Escitalopram. Journal of Clinical Pharmacology, 2009, 49, 176-184.	2.0	13
153	Sensitivity to Change and Predictive Validity of the MOODS-SR Questionnaire, Last-Month Version. Psychotherapy and Psychosomatics, 2009, 78, 116-124.	8.8	13
154	Deep Brain Stimulation of the Anterior Limb of the Internal Capsule May Be Efficacious for Explosive Aggressive Behaviour. Stereotactic and Functional Neurosurgery, 2016, 94, 371-378.	1.5	13
155	Internet use by older adults with bipolar disorder: international survey results. International Journal of Bipolar Disorders, 2018, 6, 20.	2.2	13
156	Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity. Frontiers in Psychiatry, 2019, 9, 784.	2.6	13
157	The Putative Impact of Metabolic Health on Default Mode Network Activity and Functional Connectivity in Neuropsychiatric Disorders. CNS and Neurological Disorders - Drug Targets, 2015, 13, 1750-1758.	1.4	13
158	Emotional blunting in patients with depression. Part I: clinical characteristics. Annals of General Psychiatry, 2022, 21, 10.	2.7	13
159	A Pilot, 15-month, randomised effectiveness trial of Risperidone long-acting injection (RLAI) versus oral atypical antipsychotic agents (AAP) in persons with bipolar disorder. Acta Neuropsychiatrica, 2010, 22, 68-80.	2.1	12
160	Cost-Effectiveness of Asenapine in the Treatment of Patients with Bipolar I Disorder with Mixed Episodes in an Italian Context. Advances in Therapy, 2014, 31, 873-890.	2.9	12
161	Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics. Neuropsychiatric Disease and Treatment, 2016, 12, 99.	2.2	12
162	Assessment of de novo copy-number variations in Italian patients with schizophrenia: Detection of putative mutations involving regulatory enhancer elements. World Journal of Biological Psychiatry, 2019, 20, 126-136.	2.6	12

#	Article	IF	CITATIONS
163	Photosensitivity and panic-agoraphobic spectrum: a pilot study. Rivista Di Psichiatria, 2013, 48, 108-12.	0.6	12
164	Older and Newer Strategies for the Pharmacological Management of Agitation in Patients with Bipolar Disorder or Schizophrenia. CNS and Neurological Disorders - Drug Targets, 2018, 16, 885-890.	1.4	12
165	Cross-cultural validity of the Structured Clinical Interview for Panic-Agoraphobic Spectrum. Social Psychiatry and Psychiatric Epidemiology, 2005, 40, 283-290.	3.1	11
166	Switching among Antipsychotics in Everyday Clinical Practice: Focus on Ziprasidone. Postgraduate Medicine, 2011, 123, 135-159.	2.0	11
167	Practical guidance for prescribing trazodone extended-release in major depression. Expert Opinion on Pharmacotherapy, 2016, 17, 433-441.	1.8	11
168	Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists. Expert Opinion on Drug Safety, 2016, 15, 449-455.	2.4	11
169	Pharmacological treatment of mixed states. CNS Spectrums, 2017, 22, 186-195.	1.2	11
170	Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice. Rivista Di Psichiatria, 2019, 54, 137-149.	0.6	11
171	Factors associated with lifetime suicide attempts in bipolar disorder: results from an Italian nationwide study. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 359-370.	3.2	11
172	Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment. CNS Spectrums, 2023, 28, 90-97.	1.2	11
173	Comparative outcomes among the problem areas of interpersonal psychotherapy for depression. Depression and Anxiety, 2010, 27, 434-440.	4.1	10
174	Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder. Expert Opinion on Pharmacotherapy, 2010, 11, 1727-1740.	1.8	10
175	Season of Birth Is Associated With Adult Body Mass Index in Patients With Bipolar Disorder. Chronobiology International, 2013, 30, 577-582.	2.0	10
176	The Effects of Terrorist Attacks on Symptom Clusters of PTSD: a Comparison with Victims of Other Traumatic Events. Psychiatric Quarterly, 2019, 90, 587-599.	2.1	10
177	Psychomotor agitation and hyperactive delirium in COVID-19 patients treated with aripiprazole 9.75 mg/1.3 ml immediate release. Psychopharmacology, 2020, 237, 3497-3501.	3.1	10
178	Autism spectrum in patients with schizophrenia: correlations with real-life functioning, resilience, and coping styles. CNS Spectrums, 2021, , 1-11.	1.2	10
179	Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder. Psychopharmacology Bulletin, 2006, 39, 120-46.	0.0	10
180	Quality of life and subthreshold obsessive-compulsive disorder. Acta Neuropsychiatrica, 2007, 19, 357-361.	2.1	9

#	Article	IF	CITATIONS
181	Light Therapy as a Treatment for Sexual Dysfunctions. Psychotherapy and Psychosomatics, 2009, 78, 127-128.	8.8	9
182	Correlates of current rapid-cycling bipolar disorder: Results from the Italian multicentric RENDiBi study. European Psychiatry, 2019, 62, 82-89.	0.2	9
183	Attitudes of Italian Psychiatrists Toward the Evaluation of Physical Comorbidities and Sexual Dysfunction in Patients With Schizophrenia. Implications for Clinical Practice. Frontiers in Psychiatry, 2019, 10, 842.	2.6	9
184	Schizophrenia and "unmet needs― From diagnosis to care in Italy. European Psychiatry, 2020, 63, e26.	0.2	9
185	Medical Monitoring in Patients With Bipolar Disorder. Journal of Clinical Psychiatry, 2008, 69, e16.	2.2	9
186	Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opinion on Pharmacotherapy, 2013, 14, 489-504.	1.8	8
187	Five-year follow-up of first-episode depression treated with psychodynamic psychotherapy or antidepressants. Psychiatry Research, 2019, 275, 27-30.	3.3	8
188	Real-world effectiveness of long acting aripiprazole: Treatment persistence and its correlates in the Italian clinical practice. Psychiatry Research, 2019, 272, 698-706.	3.3	8
189	Mood spectrum symptoms during a major depressive episode: Differences between 145 patients with bipolar disorder and 155 patients with major depressive disorder. Arguments for a dimensional approach. Bipolar Disorders, 2020, 22, 385-391.	1.9	8
190	One Month Weight Loss Predicts the Efficacy of Liraglutide in Obese Patients: Data from A Single Center. Endocrine Practice, 2020, 26, 235-240.	2.1	8
191	Metacognitions and repetitive negative thinking in bipolar disorder and healthy controls: A comparative study. Journal of Affective Disorders, 2020, 276, 152-158.	4.1	8
192	Development and preliminary testing of the General 5-Spectrum Measure (GSM-V). Depression and Anxiety, 2003, 18, 109-117.	4.1	7
193	The Rabbit Syndrome: State of the Art. Current Clinical Pharmacology, 2007, 2, 212-216.	0.6	7
194	Integrating Medical and Psychiatric Care in Patients With Bipolar Disorder. Journal of Clinical Psychopharmacology, 2008, 28, 257-258.	1.4	7
195	Aripiprazole for the treatment of bipolar disorder: a review of current evidence. Expert Opinion on Pharmacotherapy, 2011, 12, 473-488.	1.8	7
196	On the centrality of mixed features in mood disorders: Listening to Kraepelin and Weygandt and moving forward. Bipolar Disorders, 2017, 19, 704-705.	1.9	7
197	A study on the association of mood disorders and gluten-related diseases. Psychiatry Research, 2018, 260, 366-370.	3.3	7
198	A comparison of physical comorbidities in patients with posttraumatic stress disorder developed after a terrorist attack or other traumatic event. Journal of Neuroscience Research, 2019, 97, 543-553.	2.9	7

#	Article	IF	Citations
199	PTSD in victims of terroristic attacks – a comparison with the impact of other traumatic events on patients' lives. Psychiatria Polska, 2016, 50, 907-921.	0.5	7
200	Cariprazine in the management of negative symptoms of schizophrenia: stateÂofÂtheÂart and future perspectives. Future Neurology, 2020, 15, .	0.5	7
201	Bipolar Disorder Center for Pennsylvanians: Implementing an Effectiveness Trial to Improve Treatment for At-Risk Patients. Psychiatric Services, 2009, 60, 888-97.	2.0	7
202	Quality of life and subthreshold affective symptoms. Quality of Life Research, 2005, 14, 905-909.	3.1	6
203	Outcome and predictors of remission in bipolar-I patients experiencing manic episode and treated with oral antipsychotics and/or mood stabilizers. International Clinical Psychopharmacology, 2018, 33, 131-139.	1.7	6
204	Post-traumatic stress disorder in Italy: a comprehensive evaluation of all the ICD comorbidities and gender-related differences. BMC Research Notes, 2019, 12, 747.	1.4	6
205	Lithium and valproate serum level fluctuations within the menstrual cycle. International Clinical Psychopharmacology, 2019, 34, 143-150.	1.7	6
206	Treatment of Agitation With Lorazepam in Clinical Practice: A Systematic Review. Frontiers in Psychiatry, 2021, 12, 628965.	2.6	6
207	Variations in seasonal solar insolation are associated with a history of suicide attempts in bipolar I disorder. International Journal of Bipolar Disorders, 2021, 9, 26.	2.2	6
208	Overcoming hurdles to achieving good physical health in patients treated with atypical antipsychotics. European Neuropsychopharmacology, 2008, 18, S101-S107.	0.7	5
209	Bipolar Disorder Center for Pennsylvanians: Implementing an Effectiveness Trial to Improve Treatment for At-Risk Patients. Psychiatric Services, 2009, 60, 888-897.	2.0	5
210	C-QUALITY: Cost and Quality-of-Life Pharmacoeconomic Analysis of Antidepressants in Major Depressive Disorder in Italy. Advances in Therapy, 2013, 30, 697-712.	2.9	5
211	Assessing patient-rated vs. clinician-rated adherence to the therapy in treatment resistant schizophrenia, schizophrenia responders, and non-schizophrenia patients. Psychiatry Research, 2017, 249, 159-166.	3.3	5
212	Healthcare professionals' perceptions on the emotional impact of having an inadequate response to antidepressant medications: survey and prospective patient audit. Annals of General Psychiatry, 2018, 17, 20.	2.7	5
213	Advances in treatment for postpartum major depressive disorder. Expert Opinion on Pharmacotherapy, 2020, 21, 1685-1698.	1.8	5
214	Outcomes associated with different vaccines in individuals with bipolar disorder and impact on the current COVID-19 pandemic- a systematic review. European Neuropsychopharmacology, 2022, 54, 90-99.	0.7	5
215	Non-monoaminergic targets for the development of antidepressants: focus on neuropeptides. Mini-Reviews in Medicinal Chemistry, 2013, 13, 2-10.	2.4	5
216	Changes in metabolic syndrome parameters in patients with schizoaffective disorder who participated in a randomized, placebo-controlled trial of topiramate. Asian Journal of Psychiatry, 2009, 2, 106-111.	2.0	4

#	Article	IF	CITATIONS
217	Adherence to escitalopram treatment in depression. International Clinical Psychopharmacology, 2012, 27, 1.	1.7	4
218	Predictors of Depressive Switch in Patients With Bipolar I Disorder Who Initiated or Changed Pharmacologic Treatment for Mania or Mixed-Mania. Journal of Clinical Psychiatry, 2020, 81, .	2.2	4
219	Biomarkers, Inflammation, and Bipolar Disorder: Association Between the Improvement of Bipolar Disorder Severity and the Improvement in C-Reactive Protein Levels After 7 Days of Inpatient Treatment. Frontiers in Psychiatry, 2021, 12, 803034.	2.6	4
220	Principi di farmacodinamica e farmacocinetica nello switch tra antipsicotici: focus su cariprazina. Rivista Di Psichiatria, 2019, 54, 1-6.	0.6	4
221	Exploration of mood spectrum symptoms during a major depressive episode: The impact of contrapolarityâ€"Results from a transdiagnostic cluster analysis on an Italian sample of unipolar and bipolar patients. European Psychiatry, 2022, 65, .	0.2	4
222	Emotional blunting in patients with depression. Part II: relationship with functioning, well-being, and quality of life. Annals of General Psychiatry, 2022, 21, .	2.7	4
223	The long term — Maximising potential for rehabilitation in patients with schizophrenia. European Neuropsychopharmacology, 2007, 17, S123-S129.	0.7	3
224	A new approach for seasonal pattern: is it related to bipolarity dimension? Findings from an Italian multicenter study. International Journal of Psychiatry in Clinical Practice, 2021, 25, 73-81.	2.4	3
225	Which mixed depression model? A comparison between DSMâ€5â€defined mixed features and Koukopoulos' criteria. Bipolar Disorders, 2022, 24, 530-538.	1.9	3
226	Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis. Frontiers in Psychiatry, 2022, 13, 877867.	2.6	3
227	Physical health considerations in psychiatry: European views on recognition, monitoring and management. European Neuropsychopharmacology, 2008, 18, iii.	0.7	2
228	Panic agoraphobic spectrum in psychiatrically healthy subjects: Impact on quality of life. Epidemiologia E Psichiatria Sociale, 2009, 18, 65-68.	0.9	2
229	An approach to revealing clinically relevant subgroups across the mood spectrum. Journal of Affective Disorders, 2016, 203, 265-274.	4.1	2
230	Patient Safety and Risk Management in Mental Health. , 2021, , 287-298.		2
231	Clinical effectiveness of parenteral trazodone for the management of psychomotor activation in patients with bipolar disorder. Neuroendocrinology Letters, 2018, 39, 205-208.	0.2	2
232	Emotional blunting in patients with depression. Part III: relationship with psychological trauma. Annals of General Psychiatry, 2022, 21, .	2.7	2
233	Circadian neuromarkers of mood disorders. Journal of Affective Disorders Reports, 2022, 10, 100384.	1.7	2
234	Appropriate treatments for agitation associated with schizophrenia: Control of acute agitation and maintenance of efficacy. European Psychiatry, 2007, 22, S89-S90.	0.2	1

#	Article	IF	CITATIONS
235	Aripiprazole: a discussion on its clinical use in mania associated with bipolar I disorder. Drugs and Therapy Perspectives, 2008, 24, 1.	0.6	1
236	Quetiapine in post-transplant acute mania/bipolar disorder NOS. International Journal of Neuropsychopharmacology, 2008, 11, 723-4.	2.1	1
237	Bipolar spectrum: just broadening or an integration between categories and dimensions?. World Psychiatry, 2011, 10, 192-193.	10.4	1
238	Non-Monoaminergic Targets for the Development of Antidepressants: Focus on Neuropeptides. Mini-Reviews in Medicinal Chemistry, 2012, 13, 2-10.	2.4	1
239	C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional Italian settings of Veneto and Sardinia. ClinicoEconomics and Outcomes Research, 2013, 5, 611.	1.9	1
240	Binge Eating Disorder. Journal of Addiction Medicine, 2015, 9, 20-24.	2.6	1
241	Convergence between clinicianâ€rated and patientâ€reported PTSD symptoms in a specialized outpatient service: The moderator role of gender. Perspectives in Psychiatric Care, 2021, 57, 761-769.	1.9	1
242	Effectiveness of Intramuscular Chlorpromazine for Rapid Treatment of Psychomotor Agitation. Journal of Clinical Psychopharmacology, 2021, 41, 613-614.	1.4	1
243	Physical Activity Monitoring Preferences in Adults With Bipolar Disorder. Frontiers in Psychiatry, 2021, 12, 657043.	2.6	1
244	Unmet Needs in the Assessment and Treatment of Psychomotor Agitation. , 2020, , 109-123.		1
245	Impact of menstrual cycle events on bipolar disorder course: a narrative review of current evidence. Archives of Women's Mental Health, 2022, 25, 257-266.	2.6	1
246	Emotional blunting in patients with depression. Part IV: differences between patient and physician perceptions. Annals of General Psychiatry, 2022, 21, .	2.7	1
247	Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder. Expert Opinion on Pharmacotherapy, 2011, 12, 2245-2263.	1.8	0
248	P.1.i.021 EMDR efficacy on characteristic posttraumatic stress disorder neurobiological alterations. European Neuropsychopharmacology, 2014, 24, S309.	0.7	0
249	Starting aripiprazole long-acting-once-a-month early in treatment: why, how and for whom? Expert consensus and practical recommendations by a panel of Italian clinicians. Expert Opinion on Pharmacotherapy, 2016, 17, 2143-2147.	1.8	0
250	Effect of long-term valproate treatment on bone metabolism in patients with bipolar disorder: a pilot study. European Neuropsychopharmacology, 2017, 27, S867-S868.	0.7	0
251	Medication-Associated Sexual Dysfunction in Patients with Mental Illness. Trends in Andrology and Sexual Medicine, 2018, , 251-262.	0.1	0
252	Bipolar Disorders., 0,, 155-174.		0